Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Good Day

<< Previous

Bullboard Posts

Next >>

Post by JPkatzon May 07, 2021 10:26pm

403 Views

Post# 33158766

Good Day

Although I do think it was quite the scheme over the years to hose retail with endless dilution while Dan and Wallace position in AH remained unaffected.. And now that dilution may never be an issue moving forward, I think this is the turning point because they are finally aligned with shareholders! I added 10k worth of shares today to my position... Finally Dan is on our side!!!
Thanks to all who tried to keep Dan somewhat accountable.. perhaps that is why we reached a somewhat favourable agreement for all stakeholders!

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China